Get the Stockscreener App
47.50
247.73%
33.84
Pre-market:
52.16
4.66
+9.81%
Uniqure N V stock is traded at $47.50, with a volume of 69.72M.
It is up +247.73% in the last 24 hours and up +202.55% over the past month.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
See More
Previous Close:
$13.66
Open:
$39.36
24h Volume:
69.72M
Relative Volume:
31.99
Market Cap:
$2.61B
Revenue:
$14.34M
Net Income/Loss:
$-199.00M
P/E Ratio:
-12.12
EPS:
-3.92
Net Cash Flow:
$-183.51M
1W Performance:
+235.45%
1M Performance:
+202.55%
6M Performance:
+221.60%
1Y Performance:
+824.12%
1-Day Range:
$37.12
$51.21
1-Week Range:
$13.65
$51.21
52-Week Range:
$4.45
$51.21
Uniqure N V Stock (QURE) Company Profile
Name
Uniqure N V
Sector
Industry
Phone
1-339-970-7000
Address
PAASHEUVELWEG 25A, AMSTERDAM
Compare QURE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QURE
Uniqure N V
|
47.50 | 749.48M | 14.34M | -199.00M | -183.51M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
376.62 | 97.36B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
576.98 | 60.19B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.37 | 59.56B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
729.76 | 44.94B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
329.84 | 36.14B | 3.81B | -644.79M | -669.77M | -6.24 |
Uniqure N V Stock (QURE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-14-25 | Upgrade | Mizuho | Neutral → Outperform |
| Apr-01-25 | Resumed | Chardan Capital Markets | Buy |
| Dec-10-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Feb-29-24 | Downgrade | Goldman | Buy → Neutral |
| Dec-19-23 | Downgrade | Mizuho | Buy → Neutral |
| Mar-17-22 | Upgrade | UBS | Neutral → Buy |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| May-21-21 | Initiated | UBS | Neutral |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Apr-01-21 | Upgrade | Mizuho | Neutral → Buy |
| Jan-07-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-24-20 | Initiated | H.C. Wainwright | Buy |
| Nov-11-20 | Initiated | Berenberg | Buy |
| Nov-09-20 | Initiated | Jefferies | Buy |
| Nov-04-20 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-23-20 | Initiated | RBC Capital Mkts | Outperform |
| Aug-25-20 | Initiated | Raymond James | Strong Buy |
| Jul-31-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jun-25-20 | Downgrade | Mizuho | Buy → Neutral |
| Jun-25-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-25-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-03-19 | Initiated | Cowen | Outperform |
| Dec-03-19 | Initiated | Goldman | Buy |
| Nov-05-19 | Initiated | Credit Suisse | Outperform |
| Oct-11-19 | Initiated | Stifel | Buy |
| Sep-25-19 | Initiated | Bernstein | Outperform |
| Sep-12-19 | Initiated | Mizuho | Buy |
| Jul-30-19 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-08-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Apr-12-19 | Initiated | Piper Jaffray | Overweight |
| Mar-29-19 | Initiated | Robert W. Baird | Outperform |
View All
Uniqure N V Stock (QURE) Latest News
uniQure stock rises after positive Huntington’s disease gene therapy data - Investing.com
uniQure stock price target doubled to $60 by Mizuho on Huntington’s therapy data - Investing.com UK
uniQure Secures $175 Million Loan Amendment - TipRanks
UniQure’s stocks up after AMT-130 trial win - European Biotechnology Magazine
BABA, INTC, QURE, TSLA, OPEN: 5 Trending Stocks TodayAlibaba Gr Hldgs (NYSE:BABA), Intel (NASDAQ:INTC) - Benzinga
Top Stocks today: uniQure, Lithium Americas and Tesla soar - Yahoo Finance
uniQure launches $200 million public offering of ordinary shares By Investing.com - Investing.com Australia
uniQure stock soars after positive Huntington’s disease drug results - Investing.com
uniQure (QURE) Stock: Soars 247% on $200 Million Public Offering Plan - parameter.io
uniQure (QURE) Analyst Raises Price Target to $68 With Outperform Rating | QURE Stock News - GuruFocus
UniQure Stock Soars: Too Late to Buy? - timothysykes.com
Top stocks today: Tesla, uniQure, and Lithium Americas soar - TheStreet
uniQure (QURE) Launches $200M Public Offering, Sees After-Hours Stock Surge - GuruFocus
Experimental gene therapy found to slow Huntington’s disease progression, company says - CNN
UniQure Stock Hits 5-Year High As Analysts Hail Huntington’s Therapy Data — Retail Spots ‘Diamond In Rough Of Biotech’ - Stocktwits
uniQure launches $200 million public offering of ordinary shares - Investing.com
Uniqure stock soars over 247% today after breakthrough Huntington’s disease drug results - The Economic Times
UniQure launches $200 mln equity offering after shares skyrocket - TradingView
uniQure (QURE) Initiates $200 Million Public Offering - GuruFocus
uniQure announces $200 million proposed public offering - MSN
uniQure announces $200M ordinary shares offering - TipRanks
Here’s why biotech UniQure’s stock just tripled, and brought ClearPoint shares up with it - MarketWatch
UniQure Huntington’s Gene Therapy Launch Planning Underway - insights.citeline.com
uniQure Announces $200 Million Proposed Public Offering - The Manila Times
uniQure: Positive 3-Year AMT-130 Data Leads To Pre-BLA FDA Meeting And Beyond (QURE) - Seeking Alpha
Hunting down Huntington’s: Uniqure’s pivotal win - BioWorld MedTech
UniQure Celebrates A Groundbreaking Moment For Huntington’s Disease - insights.citeline.com
$200 Million Share Offering: Gene Therapy Leader uniQure Seeks Capital for Transformative Therapies - Stock Titan
Promising Medical Stocks To Watch TodaySeptember 24th - MarketBeat
Stifel Raises Price Target for uniQure (QURE) to 65.00 USD | QUR - GuruFocus
uniQure (NASDAQ:QURE) Given New $65.00 Price Target at Stifel Nicolaus - MarketBeat
Gene Therapy Breakthrough: uniQure’s QURE Stock Skyrockets on Huntington’s Triumph - ts2.tech
This Stock Is Tripling on a Key Gene Therapy Win. Should You Buy the 200%-Plus Surge Now? - inkl
uniQure (NASDAQ:QURE) Given New $68.00 Price Target at Leerink Partners - MarketBeat
uniQure stock price target raised to $68 from $48 at Leerink Partners - Investing.com Canada
What's Going On With UniQure Stock Wednesday? - Benzinga
Lithium Americas, Alibaba, uniQure, IREN, Cidara: Stocks Making The Biggest Moves Today - MSN
UniQure's Shares Soar After Phase 1/2 Trial in Huntington's Disease Meets Primary Endpoint - MarketScreener
uniQure Stock Doubles On Promising Data From Huntington's Disease Trial - AOL.com
First Successful Gene Therapy for Huntington's Disease Slows Disease Progression by 75% - inkl
A Cure For Huntington's Disease? UniQure Launches Nearly 250%. - inkl
uniQure (QURE) Sees Positive Results in Huntington's Disease Trials - GuruFocus
uniQure (QURE) Receives Consistent Buy Rating from HC Wainwright & Co. | QURE Stock News - GuruFocus
uniQure (NASDAQ:QURE) Given "Buy" Rating at HC Wainwright - MarketBeat
Uniqure stock soars 196% after breakthrough Huntington’s disease drug results - The Economic Times
uniQure (NASDAQ:QURE) Sets New 52-Week HighTime to Buy? - MarketBeat
uniQure (QURE) Shows Promising Results in Huntington's Disease S - GuruFocus
uniQure Announces Refinancing of Existing $50M Debt and Securing Up to an Additional $125M In Funding - citybiz
uniQure (QURE) Stock Jumps 150% on Breakthrough Huntington’s Disease Data - parameter.io
Transcript : UniQure N.V.Special Call - MarketScreener
uniQure Leaps on Huntington Test Results - Baystreet.ca
Uniqure N V Stock (QURE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.30%
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):